AFFYMAX/HGS AUTOMATED SCREENING/GENOMICS COMBINATION WOULD BE ONE OUTCOME OF GLAXO/SMITHKLINE MERGER; R&D CONSOLIDATION LIKELY TO SPUR START-UPS
Executive Summary
The 1995 merger of Glaxo and Wellcome is an apt model for the likely impact of a consolidation of SmithKline Beecham and Glaxo Wellcome's R&D operations: substantial downsizing by the newly merged firm accompanied by a flowering of smaller start-ups and new spin-offs.